Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
238 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Bristol-Myers Squibb Company - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bristol-Myers Squibb Company including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bristol-Myers Squibb Company's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bristol-Myers Squibb Company's pipeline products Reasons to buy - Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bristol-Myers Squibb Company and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bristol-Myers Squibb Company - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Bristol-Myers Squibb Company Snapshot 7 Bristol-Myers Squibb Company Overview 7 Key Information 7 Key Facts 7 Bristol-Myers Squibb Company - Research and Development Overview 8 Key Therapeutic Areas 8 Bristol-Myers Squibb Company - Pipeline Review 17 Pipeline Products by Stage of Development 17 Pipeline Products - Monotherapy 18 Pipeline Products - Combination Treatment Modalities 19 Pipeline Products - Partnered Products 20 Pipeline Products - Out-Licensed Products 23 Bristol-Myers Squibb Company - Pipeline Products Glance 27 Bristol-Myers Squibb Company - Late Stage Pipeline Products 27 Bristol-Myers Squibb Company - Clinical Stage Pipeline Products 29 Bristol-Myers Squibb Company - Early Stage Pipeline Products 35 Bristol-Myers Squibb Company - Drug Profiles 39 (atazanavir sulfate + cobicistat) 39 apixaban 41 asunaprevir 43 asunaprevir + daclatasvir 45 daclatasvir 47 (daclatasvir + asunaprevir + beclabuvir) 49 abatacept 50 beclabuvir 53 ipilimumab 55 ixabepilone 58 nivolumab 60 peginterferon lambda-1a 64 BMS-663068 66 BMS-690514 68 BMS-754807 70 BMS-813160 72 BMS-817399 73 BMS-833923 74 BMS-919373 76 BMS-954561 77 BMS-955176 78 BMS-986020 79 BMS-986036 80 censavudine 81 clazakizumab 82 dasatinib 84 eldelumab 87 lirilumab 89 pegdinetanib 90 rimegepant 92 Small Molecule for HIV 94 Triple Reuptake Inhibitors 95 BMS-911543 96 Anti-CD40 Antibody Program 98 Antibody Targeting CD40 Ligand for Immunology 99 BMS-241027 100 BMS-262084 101 BMS-394136 102 BMS-777607 103 BMS-906024 104 BMS-933043 105 BMS-936559 106 BMS-962476 107 BMS-981164 108 BMS-986016 109 BMS-986046 110 BMS-986089 111 BMS-986115 112 denenicokin 113 Iso-fludelone 115 MDX-1203 117 MDX-1303 118 MDX-1401 120 MDX-1411 121 Monoclonal Antibody to Antagonize CD28 for Immunology 122 Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 123 ulocuplumab 124 urelumab 125 XL-652 127 BMS-817378 129 Acrylamide (S)-6 130 ALB-109780 131 ARX-720 Relaxin 132 BMS-299897 133 BMS-457 134 BMS-585248 135 BMS-593214 136 BMS-795311 137 BMS-816106 138 BMS-871 139 Drug For Cancer 140 EGFR/IGFR Tandem Adnectin 141 EHT/AGN-0002 142 IPN-002 143 IPN-007 144 noscapine 145 Small Molecule to Inhibit Factor XIa for Thrombosis 146 Small Molecule to Inhibit P2Y1 for Thrombosis 147 Small Molecules to Inhibit ROR for Inflammation 148 Bicyclic Triazoles 149 Bispecific Antibody for Non-Hodkins Lymphoma 150 Bruton's Tyrosine Kinase Inhibitor 151 Drug For Metabolic Disorders 152 Monoclonal Antibodies for Cancer 153 Monoclonal Antibodies Targeting Complement System 154 Monoclonal Antibodies Targeting Tau Protein 155 Monoclonal Antibodies to Target CTLA-4 for Cancer 156 Next Generation Antibody Drug Conjugates for Oncology 157 Proteins for Immunology and Cancer 158 Small Molecules for Undisclosed Indication 159 Bristol-Myers Squibb Company - Pipeline Analysis 160 Bristol-Myers Squibb Company - Pipeline Products by Target 160 Bristol-Myers Squibb Company - Pipeline Products by Route of Administration 165 Bristol-Myers Squibb Company - Pipeline Products by Molecule Type 166 Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action 168 Bristol-Myers Squibb Company - Recent Pipeline Updates 173 Bristol-Myers Squibb Company - Dormant Projects 207 Bristol-Myers Squibb Company - Discontinued Pipeline Products 216 Discontinued Pipeline Product Profiles 217 Bristol-Myers Squibb Company - Company Statement 222 Bristol-Myers Squibb Company - Locations And Subsidiaries 225 Head Office 225 Other Locations & Subsidiaries 225 Bristol-Myers Squibb Company - Key Manufacturing Facilities 230 Appendix 231 Methodology 231 Coverage 231 Secondary Research 231 Primary Research 231 Expert Panel Validation 231 Contact Us 232 Disclaimer 232
List of Tables Bristol-Myers Squibb Company, Key Information 13 Bristol-Myers Squibb Company, Key Facts 13 Bristol-Myers Squibb Company - Pipeline by Indication, 2014 16 Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2014 23 Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2014 24 Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2014 25 Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2014 26 Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2014 27 Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2014 29 Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2014 30 Bristol-Myers Squibb Company - Pre-Registration, 2014 33 Bristol-Myers Squibb Company - Phase III, 2014 34 Bristol-Myers Squibb Company - Phase II, 2014 35 Bristol-Myers Squibb Company - Phase I, 2014 38 Bristol-Myers Squibb Company - IND/CTA Filed, 2014 41 Bristol-Myers Squibb Company - Preclinical, 2014 42 Bristol-Myers Squibb Company - Discovery, 2014 44 Bristol-Myers Squibb Company - Pipeline by Target, 2014 167 Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2014 171 Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2014 173 Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2014 175 Bristol-Myers Squibb Company - Recent Pipeline Updates, 2014 179 Bristol-Myers Squibb Company - Dormant Developmental Projects,2014 213 Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2014 222 Bristol-Myers Squibb Company, Other Locations 231 Bristol-Myers Squibb Company, Subsidiaries 232 Bristol-Myers Squibb Company, Key Manufacturing Facilities 236
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
